Targacept and AstraZeneca Initiate Phase II Trial of Neuronal Nicotinic agonist AZD3480

Targacept and AstraZeneca have initiated a phase II trial of their Neuronal Nicotinic agonist AZD3480 (TC-1734) in adults with Attention Deficit/Hyperactivity Disorder (ADHD).

NeurogesX publish Phase III data on NGX-4010 in HIV neuropathy

NeurogesX have published Phase 3 data of its lead capsaicin product NGX-4010 in Neurology. The trial, in patients with HIV-associated distal sensory polyneuropathy (HIV-DSP) showed the drug to statistically reduce pain over a 12-week period.

OSI present data on dual 5-HT1A agonist/Monoamine reuptake inhibitor

OSI have presented preclinical data on its dual 5-HT1A agonist/Monoamine reuptake inhibitor PSN602 which is under development for the treatment of obesity. It was found to cause equivalent weight loss in rats to Sibutramine

OSI present data on its GPR119 agonist for Type 2 diabetes

OSI Pharmaceuticals provided preclinical data on its GPR119 agonists PSN821 at the ADA meeting. Data showed that PSN821 has the potential to both substantially lower glucose and cause weight loss in patients with type 2 diabetes

Roches GLP-1 Taspoglutide moves into phase III

Data presented at the ADA meeting show that Roche and Ipsen’s GLP-1 analog taspoglutide demonstrates efficacy and is well tolerated in patients with type 2 diabetes. The drug is now moving in to Phase III trials.

AstraZeneca submit European application for Seroquel XR in the treatment of Major Depressive Disorder

AstraZeneca have submitted a European application for Seroquel (quetiapine fumarate) extended release Tablets for the treatment of major depressive disorder

Metabasis present data on glucagon antagonist MB07803 at ADA

Metabasis Therapeutics have presented in vivo data on its glucagon antagonist MB-07803. It was found to lower blood glucose diabetic rodents and cynomolgus monkeys